Back in August, Sanofi and the Joslin Diabetes Center announced they would team up with Google for a patient monitoring collaboration aimed at helping people with diabetes better manage their condition. Now Joslin is flying solo for its latest project, planning to launch a trial of a mobile app for Type 1 diabetes patients.
Getting patients to stick to their meds is a big problem in treating pulmonary diseases. So to boost adherence for its respiratory portfolio, Teva Pharmaceuticals is turning to technology. Read more >>
Roche is aiming to break into the multiple sclerosis field with ocrelizumab, an investigational therapy that marks the Swiss pharma giant's first foray into the disease area. And despite the big guns competing in the space, Roche may be able to corner a piece of the market for itself. Read more >>
Gilead and AbbVie may be dominating the hep C field with their next-gen combo treatments, but that doesn't mean there's no room for other companies to sneak in.
Pharma is snookered in England too. British healthcare providers are just as unhappy with drugmakers as everyone else. The newest survey finds that more than 40% of U.K. doctors view the industry negatively, reports healthcare data intelligence firm Binley's.
Publicis Health Media is marrying healthcare data to traditional media metrics for a digital mix that could cut pharma marketing costs and potentially improve patient care at the same time.
Bristol-Myers Squibb is the latest Big Pharma to pay up for bribery in China. The U.S.-based drugmaker agreed to a $14.7 million settlement with the Securities and Exchange Commission, to wrap up charges that its Chinese joint venture shelled out cash and other incentives to boost scripts for its drugs.
At Express Scripts, both Sanofi and Regeneron's Praluent and Amgen's Repatha scored a spot on the preferred formulary, which gives both PCSK9 products a chance to snare the pharmacy benefits manager's patients.
Sometimes it seems that the FDA has a scattershot approach to policing pharma marketing, with warning letters few and far between--and some of them lobbed from left field. But there's one tried-and-true way to invite unwanted attention from the agency's marketing police: Leave side effects out of drug promos, according to an analysis presented at a recent conference.